PL2509619T3 - Sposoby leczenia z zastosowaniem środków do mobilizacji komórek macierzystych i środków immunosupresyjnych - Google Patents

Sposoby leczenia z zastosowaniem środków do mobilizacji komórek macierzystych i środków immunosupresyjnych

Info

Publication number
PL2509619T3
PL2509619T3 PL10836746T PL10836746T PL2509619T3 PL 2509619 T3 PL2509619 T3 PL 2509619T3 PL 10836746 T PL10836746 T PL 10836746T PL 10836746 T PL10836746 T PL 10836746T PL 2509619 T3 PL2509619 T3 PL 2509619T3
Authority
PL
Poland
Prior art keywords
immunosuppressants
treatment
methods
stem cell
cell mobilization
Prior art date
Application number
PL10836746T
Other languages
English (en)
Inventor
Zhaoli Sun
George Melville Williams
Original Assignee
Medregen, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medregen, Llc filed Critical Medregen, Llc
Publication of PL2509619T3 publication Critical patent/PL2509619T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL10836746T 2009-12-11 2010-12-10 Sposoby leczenia z zastosowaniem środków do mobilizacji komórek macierzystych i środków immunosupresyjnych PL2509619T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28560209P 2009-12-11 2009-12-11
US31618010P 2010-03-22 2010-03-22
PCT/US2010/059877 WO2011072216A2 (en) 2009-12-11 2010-12-10 Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
EP10836746.7A EP2509619B1 (en) 2009-12-11 2010-12-10 Treatment methods utilizing stem cell mobilizers and immunosuppressive agents

Publications (1)

Publication Number Publication Date
PL2509619T3 true PL2509619T3 (pl) 2021-06-14

Family

ID=44146200

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10836746T PL2509619T3 (pl) 2009-12-11 2010-12-10 Sposoby leczenia z zastosowaniem środków do mobilizacji komórek macierzystych i środków immunosupresyjnych

Country Status (13)

Country Link
EP (2) EP2509619B1 (pl)
CY (1) CY1124082T1 (pl)
DK (1) DK2509619T3 (pl)
ES (1) ES2855428T3 (pl)
HR (1) HRP20210334T1 (pl)
HU (1) HUE053293T2 (pl)
LT (1) LT2509619T (pl)
PL (1) PL2509619T3 (pl)
PT (1) PT2509619T (pl)
RS (1) RS61543B1 (pl)
SI (1) SI2509619T1 (pl)
SM (1) SMT202100127T1 (pl)
WO (1) WO2011072216A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078746A2 (en) * 2010-12-07 2012-06-14 The Johns Hopkins University Compositions and methods for mobilizing stem cells
EP2946008A4 (en) * 2013-01-15 2016-07-20 Ohio State Innovation Foundation PROCESS FOR MOBILIZING HEMATOPOETIC STEM CELLS
CN105658217B (zh) * 2013-04-29 2021-03-19 约翰霍普金斯大学 经由自体干细胞动员的创伤愈合
CN114599359A (zh) * 2019-10-25 2022-06-07 社会福祉法人三星生命公益财团 用于提高干细胞的治疗效果的包含免疫抑制剂的组合物以及使用所述组合物提高干细胞的治疗效果的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
WO2000067776A1 (en) 1999-05-11 2000-11-16 Ortho-Mcneil Pharmaceuticals, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
MXPA02012067A (es) * 2000-06-05 2004-08-19 Univ Columbia Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
DE60137435D1 (de) 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
JP4431389B2 (ja) 2001-09-12 2010-03-10 アノーメッド インコーポレイティド 鏡像異性的に純粋なアミノ置換縮合二環式環の合成
WO2005039595A1 (ja) * 2003-10-23 2005-05-06 Chugai Pharmaceutical Co., Ltd. シクロホスファミドを有効成分とする末梢循環障害改善又は治療剤
EP1790639B1 (en) * 2004-08-27 2014-03-26 Ono Pharmaceutical Co., Ltd. Spirocyclic compounds and their use as cxcr4-antagonists
US8440199B2 (en) * 2007-12-12 2013-05-14 Imperial Innovations Limited Methods for mobilizing mesenchymal stem cells in a patient
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection

Also Published As

Publication number Publication date
DK2509619T3 (da) 2021-03-08
CY1124082T1 (el) 2022-05-27
WO2011072216A9 (en) 2011-10-13
LT2509619T (lt) 2021-04-12
EP2509619A4 (en) 2013-08-21
WO2011072216A2 (en) 2011-06-16
EP3808368B1 (en) 2026-03-04
EP2509619A2 (en) 2012-10-17
RS61543B1 (sr) 2021-04-29
EP3808368A2 (en) 2021-04-21
HUE053293T2 (hu) 2021-06-28
PT2509619T (pt) 2021-03-11
HRP20210334T1 (hr) 2021-04-02
SMT202100127T1 (it) 2021-05-07
SI2509619T1 (sl) 2021-04-30
EP3808368A3 (en) 2021-07-21
EP2509619B1 (en) 2020-12-09
ES2855428T3 (es) 2021-09-23

Similar Documents

Publication Publication Date Title
IL254144A0 (en) Methods for reprogramming cells and uses thereof
EP2467093A4 (en) JOINT DEPLOYMENT DEVICE AND METHOD OF USE
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
DK3150240T3 (da) Systemer og fremgangsmåder til fremføring af terapeutiske midler
IL222324A0 (en) Treatment of sarcoidosis using placental stem cells
GB2479020B (en) Toothbrush and method of use
DK2473034T3 (da) Frøbehandlingssammensætninger og fremgangsmåde
DK2389352T3 (da) Arginaseinhibitorer og anvendelsesfremgangsmåder
EP2414510A4 (en) INDUCED PLURIPOTENTIAL STEM CELLS
ZA201201365B (en) Plant pathogen inhibitor combinations and methods of use
DK2440253T3 (da) Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
DK2536722T3 (da) Bicycliske forbindelser og deres anvendelse som dual-c-src-/jak-inhibitorer
EP2315829A4 (en) INDUCED PLURIPOTENTIAL STEM CELLS
DK2609040T3 (da) System og fremgangsmåde til vandbehandling og -revitalisering
FI20096288A0 (fi) Formulations and methods for culturing stem cells
DK2579877T3 (da) Morpholinopyrimidiner og deres anvendelse til terapi
SG10201402428WA (en) Method of efficiently establishing induced pluripotent stem cells
PT2714059T (pt) Tratamento da dor utilizando células estaminais da placenta
BR112013011419A2 (pt) tratamento de dependência e distúrbios de controle de impulso usando inibidores de pde7
PL2523678T3 (pl) Antagoniści Wnt i sposoby leczenia
IL218738A (en) Inspection method and apparatus
DK2408794T3 (da) Isolering og oprensning af vallebestanddele
PL2611909T3 (pl) Zróżnicowanie ludzkich embrionalnych komórek macierzystych
BR112014011400A2 (pt) inibidores de nadph oxidase 4 e seus usos
BR112014009949A2 (pt) método de tratamento de hipersecreção de muco e uso de agentes